HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Senate Passes First Monograph Reform Bill After House Passed Three

Executive Summary

Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.

You may also be interested in...



Cosmetics Reform To Catch Ride On Next Coronavirus Relief Bill?

No one is saying that it will, but the Independent Cosmetic Manufacturers and Distributors is concerned that it might. The trade group is surveying its members and wider industry on COVID-19 challenges and future prospects in order to represent their interests in Washington and dissuade “uninformed cosmetics legislation.”

US Pandemic Relief Package Delivers OTC Industry Regulatory Wishes, Supplement Business Hopes

It’s unlikely any industry stakeholder or FDA official expected a bill providing emergency economic relief to consumers, industries and health care services and facilities in response to a pandemic, including extensive support opportunities for small businesses, would be the vehicle that delivers on both of the industry’s congressional wishes. The supplement industry also looks for help in CARES Act.

OTC Monograph Reform Emerges In Senate Proposal For Covid-19 Economic Relief

Senate pandemic economic relief legislation legislation would reform monograph drug program and allow purchases of OTC drugs with pre-tax health savings accounts. But lingering disagreements between Democrats and Republicans blocked the Senate's passage of the bill on 25 March.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149510

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel